Shots:
- Vivani Medical & Okava Pharmaceuticals have expanded their 2019 collaboration to develop OKV-119 for cardiometabolic conditions in dogs, which initially focused on cats
- Financial terms of the expanded agreement remain undisclosed but incl. future milestones & royalty payments to Vivani
- OKV-119 (GLP-1 receptor agonists) uses Vivani’s NanoPortal tech for steady drug delivery over time from a single implant & mimics physiological effects of fasting like improved insulin sensitivity, reduced fat mass, & improved metabolism without changing feeding routine in animals
Ref: Globenewswire | Image: Vivani Medical & Okava
Related News:- The US FDA Approves Zoetis’ Simparica Trio to Prevent Flea Tapeworm Infections in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
